Biomarkers intersect with the exposome

Biomarkers

Volumn 17, Issue 6, 2012, Pages 483-489

  Rappaport, Stephen M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biomarker; Discovery; EWAS; Exposome; Metabolomics; Proteomics

Indexed keywords

BIOLOGICAL MARKER; CD59 ANTIGEN;

BLOOD CHEMISTRY; BLOOD COMPONENT; CELIAC DISEASE; EPIDEMIOLOGY; EXPOSOME; FOLLOW UP; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HUMAN; HUNTINGTON CHOREA; KIDNEY CARCINOMA; LIQUID CHROMATOGRAPHY; METABOLOMICS; MOTOR NEURON DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PANCREAS CANCER; PROGNOSIS; PROSTATE CANCER; PROTEOMICS; REVIEW; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

BIOLOGICAL MARKERS; BLOOD PROTEINS; CARDIOVASCULAR DISEASES; ENVIRONMENTAL EXPOSURE; HUMANS; METABOLOME; METABOLOMICS; NEOPLASMS; NEURODEGENERATIVE DISEASES; PROTEOME; PROTEOMICS;

EID: 84865711795     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2012.691553     Document Type: Review

References (67)

1. Baker M. (2005). In biomarkers we trust? Nat Biotechnol 23:297-304.
2. Barba I, de Leon G, Martin E, Cuevas A, Aguade S, Candell-Riera J, Barrabes JA, Garcia-Dorado D. (2008). Nuclear magnetic resonance-based metabolomics predicts exercise-induced ischemia in patients with suspected coronary artery disease. Magn Reson Med 60:27-32.
3. BDWG. (2001). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther, 69, 89-95.
4. Beger RD, Schnackenberg LK, Holland RD, LI D, Dragan Y. (2006). Metabonomic models of human pancreatic cancer using 1D proton NMR spectra of lipids in plasma. Metabolomics, 2, 125-134.
5. Bertini I, Calabro A, De Carli V, Luchinat C, Nepi S, Porfirio B, Renzi D, Saccenti E, Tenori L. (2009). The metabonomic signature of celiac disease. J Proteome Res 8:170-177.
6. Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullman R, Bressman SS, Flint Beal M. (2008). Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 131:389-396.
7. Bones J, Byrne JC, O'Donoghue N, McManus C, Scaife C, Boissin H, Nastase A, Rudd PM. (2011). Glycomic and glycoproteomic analysis of serum from patients with stomach cancer reveals potential markers arising from host defense response mechanisms. J Proteome Res 10:1246-1265.
8. Calligaris D, Villard C, Lafitte D. (2011). Advances in top-down proteomics for disease biomarker discovery. J Proteomics 74:920-934.
9. Collins FS. (2004). The case for a US prospective cohort study of genes and environment. Nature 429:475-477.
10. Dieterle F, Marrer E. (2008). New technologies around biomarkers and their interplay with drug development. Anal Bioanal Chem 390:141-154.
11. Epel ES, Lin J, Wilhelm FH, Wolkowitz OM, Cawthon R, Adler NE, Dolbier C, Mendes WB, Blackburn EH. (2006). Cell aging in relation to stress arousal and cardiovascular disease risk factors. Psychoneuroendocrinology 31:277-287.
12. Gao H, Dong B, Liu X, Xuan H, Huang Y, Lin D. (2008). Metabonomic profiling of renal cell carcinoma: high-resolution proton nuclear magnetic resonance spectroscopy of human serum with multivariate data analysis. Anal Chim Acta 624:269-277.
13. Gerszten RE, Asnani A, Carr SA. (2011). Status and prospects for discovery and verification of new biomarkers of cardiovascular disease by proteomics. Circ Res 109:463-474.
14. Gerszten RE, Wang TJ. (2008). The search for new cardiovascular biomarkers. Nature 451:949-952.
15. Gibson G. (2008). The environmental contribution to gene expression profiles. Nat Rev Genet 9:575-581.
16. Goldstein DB. (2009). Common genetic variation and human traits. N Engl J Med 360:1696-1698.
17. Griffin JL, Atherton H, Shockcor J, Atzori L. (2011). Metabolomics as a tool for cardiac research. Nat Rev Cardiol 8:630-643.
18. Griffiths WJ, Koal T, Wang Y, Kohl M, Enot DP, Deigner HP. (2010). Targeted metabolomics for biomarker discovery. Angew Chem Int Ed Engl 49:5426-5445.
19. Hanash SM, Baik CS, Kallioniemi O. (2011). Emerging molecular biomarkers-blood-based strategies to detect and monitor cancer. Nat Rev Clin Oncol 8:142-150.
20. Hanash SM, Pitteri SJ, Faca VM. (2008). Mining the plasma proteome for cancer biomarkers. Nature 452:571-579.
21. Hiemke C. (2008). Clinical utility of drug measurement and pharmacokinetics: Therapeutic drug monitoring in psychiatry. Eur J Clin Pharmacol 64:159-166.
22. Hill AB. (1965). The environment and disease: Association or causation? Proc R Soc Med 58:295-300.
23. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS, Manolio TA. (2009). Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci USA 106:9362-9367.
24. Holmes E, Loo RL, Stamler J, Bictash M, Yap IK, Chan Q, Ebbels T, De Iorio M, Brown IJ, Veselkov KA, Daviglus ML, Kesteloot H, Ueshima H, Zhao L, Nicholson JK, Elliott P. (2008a). Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 453:396-400.
25. Holmes E, Wilson ID, Nicholson JK. (2008b). Metabolic phenotyping in health and disease. Cell 134:714-717.
26. Kitteringham NR, Jenkins RE, Lane CS, Elliott VL, Park BK. (2009). Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. J Chromatogr B Analyt Technol Biomed Life Sci 877:1229-1239.
27. Koulman A, Lane GA, Harrison SJ, Volmer DA. (2009). From differentiating metabolites to biomarkers. Anal Bioanal Chem 394:663-670.
28. LaBaer J. (2005). So, you want to look for biomarkers (introduction to the special biomarkers issue). J Proteome Res 4:1053-1059.
29. Lamb J. (2007). The Connectivity Map: A new tool for biomedical research. Nat Rev Cancer 7:54-60.
30. Lewis GD, Wei R, Liu E, Yang E, Shi X, Martinovic M, Farrell L, Asnani A, Cyrille M, Ramanathan A, Shaham O, Berriz G, Lowry PA, Palacios IF, Tasan M, Roth FP, Min J, Baumgartner C, Keshishian H, Addona T, Mootha VK, Rosenzweig A, Carr SA, Fifer MA, Sabatine MS, Gerszten RE. (2008). Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Invest 118:3503-3512.
31. Li H, Grigoryan H, Funk WE, Lu SS, Rose S, Williams ER, Rappaport SM. (2011). Profiling Cys34 adducts of human serum albumin by fixed-step selected reaction monitoring. Mol Cell Proteomics 10:M110 004606.
32. Liebler DC. (2008). Protein damage by reactive electrophiles: Targets and consequences. Chem Res Toxicol 21:117-128.
33. Lin H, Zhang J, Gao P. (2009). Silent myocardial ischemia is associated with altered plasma phospholipids. J Clin Lab Anal 23:45-50.
34. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. (2006). Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet 367:1747-1757.
35. MacQuarrie KL, Fong AP, Morse RH, Tapscott SJ. (2011). Genomewide transcription factor binding: beyond direct target regulation. Trends Genet 27:141-148.
36. Nicholson JK. (2006). Global systems biology, personalized medicine and molecular epidemiology. Mol Syst Biol 2:52.
37. Nicholson JK, Holmes E, Wilson ID. (2005). Gut microorganisms, mammalian metabolism and personalized health care. Nat Rev Microbiol 3:431-438.
38. Nordstrom A, Lewensohn R. (2010). Metabolomics: moving to the clinic. J Neuroimmune Pharmacol 5:4-17.
39. NRC. (1987). Biological markers in environmental health research. Committee on Biological Markers of the National Research Council. Environ Health Perspect, 74, 3-9.
40. Ollier W, Sprosen T, Peakman T. (2005). UK Biobank: From concept to reality. Pharmacogenomics 6:639-646.
41. Osl M, Dreiseitl S, Pfeifer B, Weinberger K, Klocker H, Bartsch G, Schafer G, Tilg B, Graber A, Baumgartner C. (2008). A new rule-based algorithm for identifying metabolic markers in prostate cancer using tandem mass spectrometry. Bioinformatics 24:2908-2914.
42. Patel CJ, Bhattacharya J, Butte AJ. (2010). An Environment-Wide Association Study (EWAS) on type 2 diabetes mellitus. PLoS ONE 5:e10746.
43. Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K, van der Schouw YT, Spencer E, Moons KG, Tjonneland A, Halkjaer J, Jensen MK, Stegger J, Clavel-Chapelon F, Boutron-Ruault MC, Chajes V, Linseisen J, Kaaks R, Trichopoulou A, Trichopoulos D, Bamia C, Sieri S, Palli D, Tumino R, Vineis P, Panico S, Peeters PH, May AM, Bueno-de-Mesquita HB, van Duijnhoven FJ, Hallmans G, Weinehall biomarkers and the exposome 4892012 Informa UK, Ltd. L, Manjer J, Hedblad B, Lund E, Agudo A, Arriola L, Barricarte A, Navarro C, Martinez C, Quiros JR, Key T, Bingham S, Khaw KT, Boffetta P, Jenab M, Ferrari P, Riboli E. (2008). General and abdominal adiposity and risk of death in Europe. N Engl J Med 359:2105-2120.
44. Rappaport SM. (2011). Implications of the exposome for exposure science. J Expo Sci Environ Epidemiol 21:5-9.
45. Rappaport SM, Smith MT. (2010). Epidemiology. Environment and disease risks. Science 330:460-461.
46. Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB. (2010a). Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: Implications for early screening and detection. BMC Med 8:13.
47. Ritchie SA, Heath D, Yamazaki Y, Grimmalt B, Kavianpour A, Krenitsky K, Elshoni H, Takemasa I, Miyake M, Sekimoto M, Monden M, Tomonaga T, Matsubara H, Sogawa K, Matsushita K, Nomura F, Goodenowe DB. (2010b). Reduction of novel circulating longchain fatty acids in colorectal cancer patients is independent of tumor burden and correlates with age. BMC Gastroenterol 10:140.
48. Ritchie SA, Jayasinghe D, Davies GF, Ahiahonu P, Ma H, Goodenowe DB. (2011). Human serum-derived hydroxy long-chain fatty acids exhibit anti-inflammatory and anti-proliferative activity. J Exp Clin Cancer Res 30:59.
49. Roux A, Lison D, Junot C, Heilier JF. (2011). Applications of liquid chromatography coupled to mass spectrometry-based metabolomics in clinical chemistry and toxicology: A review. Clin Biochem 44:119-135.
50. Rozen S, Cudkowicz ME, Bogdanov M, Matson WR, Kristal BS, Beecher C, Harrison S, Vouros P, Flarakos J, Vigneau-Callahan K, Matson TD, Newhall KM, Beal MF, Brown RH Jr, Kaddurah-Daouk R. (2005). Metabolomic analysis and signatures in motor neuron disease. Metabolomics 1:101-108.
51. Sabatine MS, Liu E, Morrow DA, Heller E, McCarroll R, Wiegand R, Berriz GF, Roth FP, Gerszten RE. (2005). Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 112:3868-3875.
52. Schadt EE, Lamb J, Yang X, Zhu J, Edwards S, Guhathakurta D, Sieberts SK, Monks S, Reitman M, Zhang C, Lum PY, Leonardson A, Thieringer R, Metzger JM, Yang L, Castle J, Zhu H, Kash SF, Drake TA, Sachs A, Lusis AJ. (2005). An integrative genomics approach to infer causal associations between gene expression and disease. Nat Genet 37:710-717.
53. Smith CJ, Perfetti TA, Garg R, Hansch C. (2003). IARC carcinogens reported in cigarette mainstream smoke and their calculated log P values. Food Chem Toxicol 41:807-817.
54. Smith GD. (2011). Epidemiology, epigenetics and the 'Gloomy Prospect': embracing randomness in population health research and practice. Int J Epidemiol 40:537-562.
55. Sturla SJ. (2007). DNA adduct profiles: Chemical approaches to addressing the biological impact of DNA damage from small molecules. Curr Opin Chem Biol 11:293-299.
56. Thomas D. (2010). Gene-environment-wide association studies: emerging approaches. Nat Rev Genet 11:259-272.
57. Tsai WL, Chung RT. (2010). Viral hepatocarcinogenesis. Oncogene 29:2309-2324.
58. Underwood BR, Broadhurst D, Dunn WB, Ellis DI, Michell AW, Vacher C, Mosedale DE, Kell DB, Barker RA, Grainger DJ, Rubinsztein DC. (2006). Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain 129:877-886.
59. Vineis P. (2004). A self-fulfilling prophecy: Are we underestimating the role of the environment in gene-environment interaction research? Int J Epidemiol 33:945-946.
60. Vineis P, Perera F. (2007). Molecular epidemiology and biomarkers in etiologic cancer research: The new in light of the old. Cancer Epidemiol Biomarkers Prev 16:1954-1965.
61. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, O'Donnell CJ, Carr SA, Mootha VK, Florez JC, Souza A, Melander O, Clish CB, Gerszten RE. (2011a). Metabolite profiles and the risk of developing diabetes. Nat Med 17:448-453.
62. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, Wu Y, Schauer P, Smith JD, Allayee H, Tang WH, DiDonato JA, Lusis AJ, Hazen SL. (2011b). Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472:57-63.
63. Wenk MR. (2005). The emerging field of lipidomics. Nat Rev Drug Discov 4:594-610.
64. Wild CP. (2005). Complementing the genome with an "exposome": The outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol Biomarkers Prev 14:1847-1850.
65. Wild CP. (2012). The exposome: From concept to utility. Int J Epidemiol 41:24-32.
66. Zhang GF, Sadhukhan S, Tochtrop GP, Brunengraber H. (2011). Metabolomics, pathway regulation, and pathway discovery. J Biol Chem 286:23631-23635.
67. Zhu J, Sova P, Xu Q, Dombek KM, Xu EY, Vu H, Tu Z, Brem RB, Bumgarner RE, Schadt EE. (2012). Stitching together Multiple Data Dimensions Reveals Interacting Metabolomic and Transcriptomic Networks That Modulate Cell Regulation. PLoS Biol 10:e1001301.